DIAPH3 governs the cellular transition to the amoeboid tumour phenotype
Therapies for most malignancies are generally ineffective once metastasis occurs. While tumour cells migrate through tissues using diverse strategies, the signalling networks controlling such behaviours in human tumours are poorly understood. Here we define a role for the Diaphanous‐related formin‐3...
Saved in:
Published in | EMBO molecular medicine Vol. 4; no. 8; pp. 743 - 760 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
01.08.2012
WILEY‐VCH Verlag EMBO Press WILEY-VCH Verlag Springer Nature |
Subjects | |
Online Access | Get full text |
ISSN | 1757-4676 1757-4684 1757-4684 |
DOI | 10.1002/emmm.201200242 |
Cover
Summary: | Therapies for most malignancies are generally ineffective once metastasis occurs. While tumour cells migrate through tissues using diverse strategies, the signalling networks controlling such behaviours in human tumours are poorly understood. Here we define a role for the Diaphanous‐related formin‐3 (DIAPH3) as a non‐canonical regulator of metastasis that restrains conversion to amoeboid cell behaviour in multiple cancer types. The
DIAPH3
locus is close to
RB1
, within a narrow consensus region of deletion on chromosome 13q in prostate, breast and hepatocellular carcinomas. DIAPH3 silencing in human carcinoma cells destabilized microtubules and induced defective endocytic trafficking, endosomal accumulation of EGFR, and hyperactivation of EGFR/MEK/ERK signalling. Silencing also evoked amoeboid properties, increased invasion and promoted metastasis in mice. In human tumours, DIAPH3 down‐regulation was associated with aggressive or metastatic disease. DIAPH3‐silenced cells were sensitive to MEK inhibition, but showed reduced sensitivity to EGFR inhibition. These findings have implications for understanding mechanisms of metastasis, and suggest that identifying patients with chromosomal deletions at
DIAPH3
may have prognostic value. |
---|---|
Bibliography: | These authors contributed equally to this work. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Present address: R&D Division, Oncology Research Laboratories, Daiichi Sankyo Europe, Munich, Germany |
ISSN: | 1757-4676 1757-4684 1757-4684 |
DOI: | 10.1002/emmm.201200242 |